Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07663136

Finding Immune Nascent Type 1 Diabetes

The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is:

What form of recruitment communication is most effective for completing a type 1diabetes home screening kit?

Researchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch).

Participants will be contacted either via email/mail or by phone and asked if they want to complete a type 1 diabetes home screening kit.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Healthy Adult Autoimmune Diseases Diabetes Mellitus Diabetes Mellitus, Type 1 Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases Type 1 Diabetes (T1D)

Age range

1 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Indiana University School of Medicine

Indianapolis, Indiana, 46202, United States

Location contact

Emily K Sims, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be in Indiana Biobank
  • Participant must be able to provide consent
  • Ages 1-99 including pregnant women

Exclusion criteria

  • Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study
  • While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening

Treatment and study plan

phone call

Behavioral

Recruitment through phone call

email/mail

Behavioral

Recruitment through email and mail

Primary outcomes

  1. Rates of Returned Home Screening Kits

    Time frame: From enrollment to the end of study at 3 years.

    The number of returned screening kits versus the number that were not returned by consented participants.

  2. Rates of Consent

    Time frame: From enrollment to the end of study at 3 years.

    The number of participants who consent versus the number of participants who do not consent.

Secondary outcomes

  1. Percent of Kits with Adequate Blood Volume

    Time frame: From enrollment to the end of study at 3 years.

Study contacts

Contact information is provided by the study sponsor or research team.

Adarsh Viswanath

CONTACT

[email protected]

317-278-5033

Maureen Mullen Montagano

CONTACT

[email protected]

317-274-7677

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Collaborators

  • Sanofi

Registry information

Official study title

Finding Immune Nascent Type 1 Diabetes (FIND T1D)

Acronym: FIND T1D

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jun 23, 2026
Registry last updated
Jun 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.